Comparison of Emergence and Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia

April 2, 2024 updated by: Juntendo University

Comparison of Emergence and Recovery Time, and Evaluation of Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia in Lung Surgery- A Pilot Study

Which is more adequate general anesthetic agent, desflurane or propofol, for emergence and recovery time, and perioperative oxygenation in lung resection surgery?

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

The investigators plan to investigate the effects of desflurane on oxygenation (prevention of HPV) of OLV compare with propofol which is used in general anesthesia for lung resection.

Transesophageal echocardiography (TEE) wiill be used to measure pulmonary blood flow during surgery visible and successively. To confirm the effect of HPV by measuring the change in pulmonary blood flow. The correlation between the blood oxygen concentration and attenuation of blood flow will be investigated.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Tokyko
      • Bunkyo-ku, Tokyko, Japan, 113-8421
        • University of Juntendo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients agree to participate in the study
  • Patients undergoing lung cancer surgery requiring one-lung ventilation.
  • American Society of Anesthesiologists Physical Status Class 1 or 2

Exclusion Criteria:

  • Patients with any of the following will be excluded from lung cancer patients.
  • New York Heart Association Classification more than 2
  • Respiratory dysfunction Vital Capacity or percent predicted Forced expiratory volume in one second is less than 50 %
  • Pulmonary hypertension with mean pulmonary arterial pressure more than 30 mmHg
  • Coagulation dysfunction
  • The administration of steroids and immunosuppressive agents within 3 months prior to surgery
  • Infection with active inflammation
  • Pneumonectomy patients
  • Cases of epidural anesthesia is contraindicated

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Desflurane
Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.

Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.

Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia.

Other Names:
  • Suprene
Active Comparator: Propofol
Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
Other Names:
  • Diprivan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxygenation
Time Frame: prior to surgery to one-hour after extubation
Arterial blood gases are monitored.Pulmonary blood flow is measured using transesophageal echocardiogram.
prior to surgery to one-hour after extubation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rapidity of Emergence From Anesthesia
Time Frame: one minute after cessation of anethetic agents to one hour after extubation
Time to extubation and orientation, where the patient is.
one minute after cessation of anethetic agents to one hour after extubation
Quality of Consiousness
Time Frame: after extubation
quality of consciousness will be assessed using Aldrete score
after extubation
Postoperative Nausea and Vomiting
Time Frame: on the postoperative day 1
degree of nausea and frequency of vomiting
on the postoperative day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Eiichi Inada, M.D., Juntendo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (Actual)

June 1, 2016

Study Completion (Estimated)

December 1, 2024

Study Registration Dates

First Submitted

December 15, 2014

First Submitted That Met QC Criteria

December 23, 2014

First Posted (Estimated)

December 24, 2014

Study Record Updates

Last Update Posted (Actual)

April 5, 2024

Last Update Submitted That Met QC Criteria

April 2, 2024

Last Verified

April 1, 2024

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer

Clinical Trials on desflurane

3
Subscribe